Brokerages Set Illumina, Inc. (NASDAQ:ILMN) Target Price at $115.00

Illumina, Inc. (NASDAQ:ILMN) has been given a consensus recommendation of “Hold” by the twenty brokerages that are covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $115.00.

A number of analysts recently weighed in on the stock. Cowen reissued a “hold” rating on shares of Illumina in a research report on Friday, October 31st. JPMorgan Chase & Co. increased their price target on Illumina from $100.00 to $105.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Daiwa America lowered Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 12th. Barclays upped their price objective on Illumina from $95.00 to $100.00 and gave the company an “underweight” rating in a research report on Friday, October 31st. Finally, Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th.

Illumina Stock Up 1.6%

Shares of ILMN opened at $121.97 on Friday. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.66. The business has a fifty day moving average of $103.75 and a 200 day moving average of $96.73. The company has a market cap of $18.64 billion, a PE ratio of 15.44, a P/E/G ratio of 2.34 and a beta of 1.42. Illumina has a 52-week low of $68.70 and a 52-week high of $153.06.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. The business had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business’s revenue was up .4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.14 earnings per share. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, sell-side analysts expect that Illumina will post 4.51 EPS for the current year.

Insiders Place Their Bets

In related news, Director Scott Gottlieb acquired 500 shares of the stock in a transaction on Monday, November 3rd. The stock was bought at an average cost of $122.13 per share, with a total value of $61,065.00. Following the transaction, the director directly owned 12,523 shares in the company, valued at approximately $1,529,433.99. This represents a 4.16% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.17% of the stock is owned by insiders.

Institutional Trading of Illumina

Several institutional investors and hedge funds have recently modified their holdings of ILMN. Assetmark Inc. increased its holdings in shares of Illumina by 10.2% in the third quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock valued at $99,000 after purchasing an additional 96 shares during the period. Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Illumina by 0.8% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock worth $1,152,000 after purchasing an additional 99 shares during the period. Versant Capital Management Inc grew its position in Illumina by 8.9% in the 3rd quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock valued at $130,000 after buying an additional 111 shares during the last quarter. Parkside Financial Bank & Trust increased its stake in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock valued at $28,000 after buying an additional 115 shares during the period. Finally, Archer Investment Corp increased its stake in Illumina by 12.9% in the 3rd quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock valued at $102,000 after buying an additional 123 shares during the period. Institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.